Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 345320, 13 pages
http://dx.doi.org/10.1155/2009/345320
Review Article

Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor- and Plasminogen Activator Inhibitor-1

1Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7035, USA
2Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
3Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA

Received 3 February 2009; Revised 18 May 2009; Accepted 10 June 2009

Academic Editor: Sarah J. Roberts-Thomson

Copyright © 2009 Jennifer C. Carter and Frank C. Church. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar
  2. D. Trichopoulos, H.-O. Adami, A. Ekbom, C.-C. Hsieh, and P. Lagiou, “Early life events and conditions and breast cancer risk: from epidemiology to etiology,” International Journal of Cancer, vol. 122, no. 3, pp. 481–485, 2008. View at Publisher · View at Google Scholar
  3. C. J. Anthony, “Risk factors associated with breast cancer,” Nurse Practitioner, vol. 3, no. 4, pp. 31–32, 1978. View at Google Scholar
  4. R. B. Wallace, B. M. Sherman, and J. A. Bean, “Menstrual cycle patterns and breast cancer risk factors,” Cancer Research, vol. 38, no. 11, pp. 4021–4024, 1978. View at Google Scholar
  5. C. P. Crum, S. C. Lester, and R. S. Cotran, “The female genital system and breast,” in Robbins Basic Pathology, V. Kumar, Ed., Saunders, Philadelphia, Pa, USA, 2003. View at Google Scholar
  6. B. Antuna-Puente, B. Feve, S. Fellahi, and J.-P. Bastard, “Adipokines: the missing link between insulin resistance and obesity,” Diabetes and Metabolism, vol. 34, no. 1, pp. 2–11, 2008. View at Publisher · View at Google Scholar
  7. N. F. Boyd, H. Guo, L. J. Martin et al., “Mammographic density and the risk and detection of breast cancer,” The New England Journal of Medicine, vol. 356, no. 3, pp. 227–236, 2007. View at Publisher · View at Google Scholar
  8. N. F. Boyd, L. J. Martin, L. Sun et al., “Body size, mammographic density, and breast cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 11, pp. 2086–2092, 2006. View at Publisher · View at Google Scholar
  9. N. F. Boyd, J. M. Rommens, K. Vogt et al., “Mammographic breast density as an intermediate phenotype for breast cancer,” Lancet Oncology, vol. 6, no. 10, pp. 798–808, 2005. View at Publisher · View at Google Scholar
  10. P. S. Steeg, “Invasion and metastasis,” Current Opinion in Oncology, vol. 4, no. 1, pp. 134–141, 1992. View at Google Scholar
  11. J. A. Lawrence, P. S. Steeg, and N. C. Institute, “Mechanisms of tumor invasion and metastasis,” World Journal of Urology, vol. 14, no. 3, pp. 124–130, 1996. View at Google Scholar
  12. N. J. MacDonald and P. S. Steeg, “Molecular basis of tumour metastasis,” Cancer Surveys, vol. 16, pp. 175–199, 1993. View at Google Scholar
  13. P. A. Andreasen, R. Egelund, and H. H. Petersen, “The plasminogen activation system in tumor growth, invasion, and metastasis,” Cellular and Molecular Life Sciences, vol. 57, no. 1, pp. 25–40, 2000. View at Publisher · View at Google Scholar
  14. A. Knoop, P. A. Andreasen, J. A. Andersen et al., “Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer,” British Journal of Cancer, vol. 77, no. 6, pp. 932–940, 1998. View at Google Scholar
  15. P. Tontonoz, E. Hu, and B. M. Spiegelman, “Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ,” Current Opinion in Genetics and Development, vol. 5, no. 5, pp. 571–576, 1995. View at Publisher · View at Google Scholar
  16. E. D. Rosen, P. Sarraf, A. E. Troy et al., “PPAR? is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999. View at Publisher · View at Google Scholar
  17. D. Paltoo, K. Woodson, P. Taylor, D. Albanes, J. Virtamo, and J. Tangrea, “Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study,” Cancer Letters, vol. 191, no. 1, pp. 67–74, 2003. View at Publisher · View at Google Scholar
  18. P. Sarraf, E. Mueller, W. M. Smith et al., “Loss-of-function mutations in PPAR? associated with human colon cancer,” Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999. View at Publisher · View at Google Scholar
  19. M. Gurnell, D. B. Savage, V. K. K. Chatterjee, and S. O'Rahilly, “The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2412–2421, 2003. View at Google Scholar
  20. M. Gurnell, “PPARγ and metabolism: insights from the study of human genetic variants,” Clinical Endocrinology, vol. 59, no. 3, pp. 267–277, 2003. View at Publisher · View at Google Scholar
  21. R. P. Brun and B. M. Spiegelman, “PPARγ and the molecular control of adipogenesis,” Journal of Endocrinology, vol. 155, no. 2, pp. 217–218, 1997. View at Publisher · View at Google Scholar
  22. D. Nagata, H. Yoshihiro, M. Nakanishi et al., “Peroxisome proliferator-activated receptor-? and growth inhibition by its ligands in prostate cancer,” Cancer Detection and Prevention, vol. 32, no. 3, pp. 259–266, 2008. View at Publisher · View at Google Scholar
  23. N. P. Nunez, H. Liu, and G. G. Meadows, “PPAR-γ ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells,” Cancer Letters, vol. 236, no. 1, pp. 133–141, 2006. View at Publisher · View at Google Scholar
  24. J. Liu, H. Lu, R. Huang et al., “Peroxisome proliferator activated receptor-? ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells,” Cancer Chemotherapy and Pharmacology, vol. 56, no. 4, pp. 400–408, 2005. View at Publisher · View at Google Scholar
  25. H. Zand, A. Rhimipour, M. Bakhshayesh, M. Shafiee, I. Nour Mohammadi, and S. Salimi, “Involvement of PPAR-γ and p53 in DHA-induced apoptosis in Reh cells,” Molecular and Cellular Biochemistry, vol. 304, no. 1-2, pp. 71–77, 2007. View at Publisher · View at Google Scholar
  26. T. Takashima, Y. Fujiwara, K. Higuchi et al., “PPAR-? ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity,” International Journal of Oncology, vol. 19, no. 3, pp. 465–471, 2001. View at Google Scholar
  27. H. Sawai, J. Liu, H. A. Reber, O. J. Hines, and G. Eibl, “Activation of peroxisome proliferator-activated receptor-γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system,” Molecular Cancer Research, vol. 4, no. 3, pp. 159–167, 2006. View at Publisher · View at Google Scholar
  28. H. Ihara, T. Urano, A. Takada, and D. J. Loskutoff, “Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones,” The FASEB Journal, vol. 15, no. 7, pp. 1233–1235, 2001. View at Google Scholar
  29. Y. Suzuki, T. Urano, H. Ihara et al., “Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in HepG2 cells,” Life Sciences, vol. 68, no. 16, pp. 1827–1837, 2001. View at Publisher · View at Google Scholar
  30. J. P. Quigley, M. B. Berkenpas, R. T. Aimes, and J. M. Chen, “Serine protease and metallo protease cascade systems involved in pericellular proteolysis,” Cell Differentiation and Development, vol. 32, no. 3, pp. 263–276, 1990. View at Publisher · View at Google Scholar
  31. M. J. Duffy, “The urokinase plasminogen activator system: role in malignancy,” Current Pharmaceutical Design, vol. 10, no. 1, pp. 39–49, 2004. View at Publisher · View at Google Scholar
  32. B. Han, M. Nakamura, I. Mori, Y. Nakamura, and K. Kakudo, “Urokinase-type plasminogen activator system and breast cancer (review),” Oncology Reports, vol. 14, no. 1, pp. 105–112, 2005. View at Google Scholar
  33. J. Y. Cho, H. C. Chung, S. H. Noh, J. K. Roh, J. S. Min, and B. S. Kim, “High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma,” Cancer, vol. 79, no. 5, pp. 878–883, 1997. View at Publisher · View at Google Scholar
  34. S. Papadopoulou, A. Scorilas, J. Yotis et al., “Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas,” Tumor Biology, vol. 23, no. 3, pp. 170–178, 2002. View at Publisher · View at Google Scholar
  35. N. Brunner, C. Pyke, C. H. Hansen, J. Romer, J. Grondahl-Hansen, and K. Dano, “Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer,” Cancer Treatment and Research, vol. 71, pp. 299–309, 1994. View at Google Scholar
  36. J. L. Fisher, C. L. Field, H. Zhou, T. L. Harris, M. A. Henderson, and P. F. M. Choong, “Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases—a comparison of normal breast tissue, non-invasive carcinoma and osseous metastases,” Breast Cancer Research and Treatment, vol. 61, no. 1, pp. 1–12, 2000. View at Publisher · View at Google Scholar
  37. D. J. Webb, D. H. D. Nguyen, M. Sankovic, and S. L. Gonias, “The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro,” Journal of Biological Chemistry, vol. 274, no. 11, pp. 7412–7420, 1999. View at Publisher · View at Google Scholar
  38. C. M. Hekman and D. J. Loskutoff, “Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants,” Journal of Biological Chemistry, vol. 260, no. 21, pp. 11581–11587, 1985. View at Google Scholar
  39. R. Verloes, G. Atassi, P. Dumont, and L. Kanarek, “Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitors,” European Journal of Cancer and Clinical Oncology, vol. 14, no. 1, pp. 23–31, 1978. View at Google Scholar
  40. I. M. Lang, K. M. Moser, and R. R. Schleef, “Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 5, pp. 808–815, 1998. View at Google Scholar
  41. H. A. Chapman Jr. and O. L. Stone, “Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor,” Biochemical Journal, vol. 230, no. 1, pp. 109–116, 1985. View at Google Scholar
  42. M. Jo, K. S. Thomas, N. Marozkina et al., “Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17449–17457, 2005. View at Publisher · View at Google Scholar
  43. C. Holst-Hansen, B. Johannessen, G. Hoyer-Hansen, J. Romer, V. Ellis, and N. Brunner, “Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness,” Clinical and Experimental Metastasis, vol. 14, no. 3, pp. 297–307, 1996. View at Google Scholar
  44. V. Costantini, A. Sidoni, R. Deveglia et al., “Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues,” Cancer, vol. 77, no. 6, pp. 1079–1088, 1996. View at Google Scholar
  45. C. Korninger, O. Wagner, and B. R. Binder, “Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator,” Journal of Laboratory and Clinical Medicine, vol. 105, no. 6, pp. 718–724, 1985. View at Google Scholar
  46. L. Strandberg, D. Lawrence, and T. Ny, “The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family,” European Journal of Biochemistry, vol. 176, no. 3, pp. 609–616, 1988. View at Google Scholar
  47. P. W. Bergum and L. A. Erickson, “Neutralization by plasminogen activator inhibitor-1 of mutants of tissue plasminogen activator,” Enzyme, vol. 40, no. 2-3, pp. 122–129, 1988. View at Google Scholar
  48. C. Masson and E. Angles-Cano, “Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator,” Biochemical Journal, vol. 256, no. 1, pp. 237–244, 1988. View at Google Scholar
  49. T.-C. Wun, M. O. Palmier, N. R. Siegel, and C. E. Smith, “Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin,” Journal of Biological Chemistry, vol. 264, no. 14, pp. 7862–7868, 1989. View at Google Scholar
  50. J. A. Foekens, M. P. Look, H. A. Peters, W. L. J. Van Putten, H. Portengen, and J. G. M. Klijn, “Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer,” Journal of the National Cancer Institute, vol. 87, no. 10, pp. 751–756, 1995. View at Google Scholar
  51. J. Grondahl-Hansen, I. J. Christensen, C. Rosenquist et al., “High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis,” Cancer Research, vol. 53, no. 11, pp. 2513–2521, 1993. View at Google Scholar
  52. M. Matsuyama and R. Yoshimura, “Peroxisome proliferator-activated receptor-γ is a potent target for prevention and treatment in human prostate and testicular cancer,” PPAR Research, vol. 2008, Article ID 249849, 2008. View at Publisher · View at Google Scholar
  53. K. Bajou, J.-M. Lewalle, C. R. Martinez et al., “Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression,” International Journal of Cancer, vol. 100, no. 5, pp. 501–506, 2002. View at Publisher · View at Google Scholar
  54. S. B. Fox, M. Taylor, J. Grondahl-Hansen, S. Kakolyris, K. C. Gatter, and A. L. Harris, “Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer,” Journal of Pathology, vol. 195, no. 2, pp. 236–243, 2001. View at Publisher · View at Google Scholar
  55. D. Palmieri, J. W. Lee, R. L. Juliano, and F. C. Church, “Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells,” Journal of Biological Chemistry, vol. 277, no. 43, pp. 40950–40957, 2002. View at Publisher · View at Google Scholar
  56. B. Chazaud, R. Ricoux, C. Christov, A. Plonquet, R. K. Gherardi, and G. Barlovatz-Meimon, “Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations,” American Journal of Pathology, vol. 160, no. 1, pp. 237–246, 2002. View at Google Scholar
  57. I. Martens, D. Ballaux, T. Funahashi et al., “Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation,” Thrombosis and Haemostasis, vol. 94, no. 6, pp. 1190–1195, 2005. View at Publisher · View at Google Scholar
  58. Y. Chen, R. C. Budd, R. J. Kelm Jr., B. E. Sobel, and D. J. Schneider, “Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1777–1783, 2006. View at Publisher · View at Google Scholar
  59. T. You, R. Yang, M. F. Lyles, D. Gong, and B. J. Nicklas, “Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors,” American Journal of Physiology, vol. 288, no. 4, pp. E741–E747, 2005. View at Publisher · View at Google Scholar
  60. M.-C. Alessi, D. Bastelica, P. Morange et al., “Plasminogen activator inhibitor 1, transforming growth factor-ß1, and BMI are closely associated in human adipose tissue during morbid obesity,” Diabetes, vol. 49, no. 8, pp. 1374–1380, 2000. View at Google Scholar
  61. F. Samad, K. T. Uysal, S. M. Wiesbrock, M. Pandey, G. S. Hotamisligil, and D. J. Loskutoff, “Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 12, pp. 6902–6907, 1999. View at Publisher · View at Google Scholar
  62. F. Samad, J. Schneiderman, and D. Loskutoff, “Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice,” Annals of the New York Academy of Sciences, vol. 811, pp. 350–360, 1997. View at Publisher · View at Google Scholar
  63. F. Samad and D. J. Loskutoff, “Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice,” Molecular Medicine, vol. 2, no. 5, pp. 568–582, 1996. View at Google Scholar
  64. B. Wang, J. R. Jenkins, and P. Trayhurn, “Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-α,” American Journal of Physiology, vol. 288, no. 4, pp. E731–E740, 2005. View at Publisher · View at Google Scholar
  65. K. Sakamoto, T. Sakamoto, and H. Ogawa, “Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 and adiponectin by adipocytes,” Circulation Journal, vol. 72, no. 5, pp. 844–846, 2008. View at Publisher · View at Google Scholar
  66. A. R. Carmichael, “Obesity as a risk factor for development and poor prognosis of breast cancer,” BJOG, vol. 113, no. 10, pp. 1160–1166, 2006. View at Publisher · View at Google Scholar
  67. A. Trentham-Dietz, P. A. Newcomb, H. B. Nichols, and J. M. Hampton, “Breast cancer risk factors and second primary malignancies among women with breast cancer,” Breast Cancer Research and Treatment, vol. 105, no. 2, pp. 195–207, 2007. View at Publisher · View at Google Scholar
  68. L. Gallicchio, M. A. McSorley, C. J. Newschaffer et al., “Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease,” Cancer Detection and Prevention, vol. 31, no. 2, pp. 95–101, 2007. View at Publisher · View at Google Scholar
  69. B. J. Caan, M. L. Kwan, G. Hartzell et al., “Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer,” Cancer Causes and Control, vol. 19, no. 10, pp. 1319–1328, 2008. View at Publisher · View at Google Scholar
  70. K. Hede, “Fat may fuel breast cancer growth,” Journal of the National Cancer Institute, vol. 100, no. 5, pp. 298–299, 2008. View at Publisher · View at Google Scholar
  71. S. D. Hursting, L. M. Lashinger, K. W. Wheatley et al., “Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 22, no. 4, pp. 659–669, 2008. View at Publisher · View at Google Scholar
  72. J. P. Bastard and L. Piéroni, “Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity,” Biomedicine and Pharmacotherapy, vol. 53, no. 10, pp. 455–461, 1999. View at Publisher · View at Google Scholar
  73. H. C. Kwaan, J. Wang, K. Svoboda, and P. J. Declerck, “Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis,” British Journal of Cancer, vol. 82, no. 10, pp. 1702–1708, 2000. View at Google Scholar
  74. E. A. Torre and R. A. Fulco, “Tumor-associated urokinase-type plasminogen activator: significance in breast cancer,” European Journal of Gynaecological Oncology, vol. 17, no. 4, pp. 315–318, 1996. View at Google Scholar
  75. T. Ueno, M. Toi, H. Saji et al., “Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer,” Clinical Cancer Research, vol. 6, no. 8, pp. 3282–3289, 2000. View at Google Scholar
  76. S. E. Bulun and E. R. Simpson, “Breast cancer and expression of aromatase in breast adipose tissue,” Trends in Endocrinology and Metabolism, vol. 5, no. 3, pp. 113–120, 1994. View at Publisher · View at Google Scholar
  77. K. J. McInnes, K. A. Brown, K. C. Knower, A. L. Chand, C. D. Clyne, and E. R. Simpson, “Characterisation of aromatase expression in the human adipocyte cell line SGBS,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 429–435, 2008. View at Publisher · View at Google Scholar
  78. S. E. Bulun, M. S. Mahendroo, and E. R. Simpson, “Aromatase gene expression in adipose tissue: relationship to breast cancer,” Journal of Steroid Biochemistry and Molecular Biology, vol. 49, pp. 319–326, 1994. View at Publisher · View at Google Scholar
  79. Y. Miki, T. Suzuki, and H. Sasano, “Controversies of aromatase localization in human breast cancer-stromal versus parenchymal cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 106, no. 1–5, pp. 97–101, 2007. View at Publisher · View at Google Scholar
  80. M. E. Grossmann, A. Ray, S. Dogan, N. K. Mizuno, and M. P. Cleary, “Balance of adiponectin and leptin modulates breast cancer cell growth,” Cell Research, vol. 18, no. 11, pp. 1154–1156, 2008. View at Publisher · View at Google Scholar
  81. C. N. Perera, H. G. Chin, N. Duru, and I. G. Camarillo, “Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression,” Journal of Endocrinology, vol. 199, no. 2, pp. 221–233, 2008. View at Publisher · View at Google Scholar
  82. M. Eriksson, O. Johnson, K. Boman et al., “Improved fibrinolytic activity during exercise may be an effect of the adipocyte-derived hormones leptin and adiponectin,” Thrombosis Research, vol. 122, no. 5, pp. 701–708, 2008. View at Publisher · View at Google Scholar
  83. R. M. E. Blumer, C. P. van Roomen, A. J. Meijer, J. H. Houben-Weerts, H. P. Sauerwein, and P. F. Dubbelhuis, “Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes,” Metabolism, vol. 57, no. 12, pp. 1655–1662, 2008. View at Publisher · View at Google Scholar
  84. T. E. Wade, A. Mathur, D. Lu, D. A. Swartz-Basile, H. A. Pitt, and N. J. Zyromski, “Adiponectin receptor-1 expression is decreased in the pancreas of obese mice,” Journal of Surgical Research, vol. 154, no. 1, pp. 78–84, 2009. View at Publisher · View at Google Scholar
  85. Y. Wang, K. S. L. Lam, and A. Xu, “Adiponectin as a negative regulator in obesity-related mammary carcinogenesis,” Cell Research, vol. 17, no. 4, pp. 280–282, 2007. View at Publisher · View at Google Scholar
  86. L. B. Tanko, A. Siddiq, C. Lecoeur et al., “ACDC/adiponectin and PPAR-? gene polymorphisms: implications for features of obesity,” Obesity Research, vol. 13, no. 12, pp. 2113–2121, 2005. View at Google Scholar
  87. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar
  88. E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPAR?,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998. View at Google Scholar
  89. M. H. Fenner and E. Elstner, “Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557–568, 2005. View at Publisher · View at Google Scholar
  90. A. P. Simopoulos, “The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases,” Experimental Biology and Medicine, vol. 233, no. 6, pp. 674–688, 2008. View at Publisher · View at Google Scholar
  91. A. P. Simopoulos, “Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases,” Biomedicine and Pharmacotherapy, vol. 60, no. 9, pp. 502–507, 2006. View at Publisher · View at Google Scholar
  92. I. M. Berquin, I. J. Edwards, and Y. Q. Chen, “Multi-targeted therapy of cancer by omega-3 fatty acids,” Cancer Letters, vol. 269, no. 2, pp. 363–377, 2008. View at Publisher · View at Google Scholar
  93. B. A. Stoll, “n-3 fatty acids and lipid peroxidation in breast cancer inhibition,” British Journal of Nutrition, vol. 87, no. 3, pp. 193–198, 2002. View at Publisher · View at Google Scholar
  94. D. Bagga, K. H. Anders, H.-J. Wang, and J. A. Glaspy, “Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer,” Nutrition and Cancer, vol. 42, no. 2, pp. 180–185, 2002. View at Google Scholar
  95. V. Maillard, P. Bougnoux, P. Ferrari et al., “n-3 and n-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in tours, France,” International Journal of Cancer, vol. 98, no. 1, pp. 78–83, 2002. View at Publisher · View at Google Scholar
  96. J. N. Fain, A. K. Madan, M. L. Hiler, P. Cheema, and S. W. Bahouth, “Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans,” Endocrinology, vol. 145, no. 5, pp. 2273–2282, 2004. View at Publisher · View at Google Scholar
  97. K. Blouin, M. Nadeau, J. Mailloux et al., “Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis,” American Journal of Physiology, vol. 296, no. 2, pp. E244–E255, 2009. View at Publisher · View at Google Scholar
  98. M. Maffei, J. Halaas, E. Ravussin et al., “Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects,” Nature Medicine, vol. 1, no. 11, pp. 1155–1161, 1995. View at Google Scholar
  99. Y. Yamazaki, Y. Kawano, and M. Uebayasi, “Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid,” Life Sciences, vol. 82, no. 5-6, pp. 290–300, 2008. View at Publisher · View at Google Scholar
  100. J. Venugopal, K. Hanashiro, and Y. Nagamine, “Regulation of PAI-1 gene expression during adipogenesis,” Journal of Cellular Biochemistry, vol. 101, no. 2, pp. 369–380, 2007. View at Publisher · View at Google Scholar
  101. L. Bahia, L. G. Aguiar, N. Villela et al., “Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome,” Clinics, vol. 61, no. 5, pp. 433–440, 2006. View at Google Scholar
  102. P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARγ2: tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994. View at Google Scholar
  103. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPAR? is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar
  104. J. Auwerx, G. Martin, M. Guerre-Millo, and B. Staels, “Transcription, adipocyte differentiation, and obesity,” Journal of Molecular Medicine, vol. 74, no. 7, pp. 347–352, 1996. View at Google Scholar
  105. P. Tontonoz, E. Hu, and B. M. Spiegelman, “Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ,” Current Opinion in Genetics and Development, vol. 5, no. 5, pp. 571–576, 1995. View at Publisher · View at Google Scholar
  106. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar
  107. C. E. Quinn, P. K. Hamilton, C. J. Lockhart, and G. E. McVeigh, “Thiazolidinediones: effects on insulin resistance and the cardiovascular system,” British Journal of Pharmacology, vol. 153, no. 4, pp. 636–645, 2008. View at Publisher · View at Google Scholar
  108. R. Dolezalova, M. M. Haluzik, L. Bosanska et al., “Effect of PPAR-? agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus,” Physiological Research, vol. 56, no. 6, pp. 741–748, 2007. View at Google Scholar
  109. R. L. C. Hoo, W. S. Chow, M. H. Yau et al., “Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2777–2782, 2007. View at Publisher · View at Google Scholar
  110. M. Igarashi, A. Hirata, H. Yamaguchi, Y. Jimbu, and M. Tominaga, “Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients,” Journal of Atherosclerosis and Thrombosis, vol. 15, no. 1, pp. 34–40, 2008. View at Google Scholar
  111. H. Shimizu, S. Oh-I, T. Tsuchiya, K.-I. Ohtani, S. Okada, and M. Mori, “Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-α levels in type 2 diabetic patients: a randomized study,” Diabetic Medicine, vol. 23, no. 3, pp. 253–257, 2006. View at Publisher · View at Google Scholar
  112. A. Galli, E. Ceni, D. W. Crabb et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR? independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004. View at Publisher · View at Google Scholar
  113. I. Takada, M. Mihara, M. Suzawa et al., “A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-? transactivation,” Nature Cell Biology, vol. 9, no. 11, pp. 1273–1285, 2007. View at Publisher · View at Google Scholar
  114. B. Relic, V. Benoit, N. Franchimont et al., “Peroxisome proliferator-activated receptor-?1 is dephosphorylated and degraded during BAY 11-7085-induced synovial fibroblast apoptosis,” Journal of Biological Chemistry, vol. 281, no. 32, pp. 22597–22604, 2006. View at Publisher · View at Google Scholar
  115. J. Han, D. P. Hajjar, J. M. Tauras, J. Feng, A. M. Gotto Jr., and A. C. Nicholson, “Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 1241–1246, 2000. View at Publisher · View at Google Scholar
  116. B. M. Spiegelman, E. Hu, J. B. Kim, and R. Brun, “PPARγ and the control of adipogenesis,” Biochimie, vol. 79, no. 2-3, pp. 111–112, 1997. View at Publisher · View at Google Scholar
  117. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar
  118. V. Costa, D. Foti, F. Paonessa et al., “The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-? (PPAR?) and thiazolidinedione- PPAR? agonists,” Endocrine-Related Cancer, vol. 15, no. 1, pp. 325–335, 2008. View at Publisher · View at Google Scholar
  119. D. Sliva, M. T. Rizzo, and D. English, “Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator,” Journal of Biological Chemistry, vol. 277, no. 5, pp. 3150–3157, 2002. View at Publisher · View at Google Scholar
  120. R. Shao, D. Karunagaran, B. P. Zhou et al., “Inhibition of nuclear factor-?B activity is involved in E1A mediated sensitization of radiation-induced apoptosis,” Journal of Biological Chemistry, vol. 272, no. 52, pp. 32739–32742, 1997. View at Publisher · View at Google Scholar
  121. C. B. Weldon, M. E. Burow, K. W. Rolfe, J. L. Clayton, B. M. Jaffe, and B. S. Beckman, “NF-κB-mediated chemoresistance in breast cancer cells,” Surgery, vol. 130, no. 2, pp. 143–150, 2001. View at Publisher · View at Google Scholar
  122. D. M. Brantley, C.-L. Chen, R. S. Muraoka et al., “Nuclear factor-?B (NF-?B) regulates proliferation and branching in mouse mammary epithelium,” Molecular Biology of the Cell, vol. 12, no. 5, pp. 1445–1455, 2001. View at Google Scholar
  123. M. Pollak, “Insulin and insulin-like growth factor signalling in neoplasia,” Nature Reviews Cancer, vol. 8, no. 12, pp. 915–928, 2008. View at Publisher · View at Google Scholar
  124. P. J. Goodwin, M. Ennis, M. Bahl et al., “High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome,” Breast Cancer Research and Treatment, vol. 114, no. 3, pp. 517–525, 2009. View at Publisher · View at Google Scholar
  125. K. B. Michels, C. G. Solomon, F. B. Hu et al., “Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study,” Diabetes Care, vol. 26, no. 6, pp. 1752–1758, 2003. View at Publisher · View at Google Scholar
  126. M. J. Borugian, S. B. Sheps, C. Kim-Sing et al., “Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer?” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 7, pp. 1163–1172, 2004. View at Google Scholar
  127. M. N. Emery, C. Leontiou, S. E. Bonner et al., “PPAR-? expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-? receptor,” Clinical Endocrinology, vol. 65, no. 3, pp. 389–395, 2006. View at Publisher · View at Google Scholar
  128. S. Vignati, V. Albertini, A. Rinaldi et al., “Cellular and molecular consequences of peroxisome proliferator-activated receptor-? activation in ovarian cancer cells,” Neoplasia, vol. 8, no. 10, pp. 851–861, 2006. View at Publisher · View at Google Scholar
  129. S. Theocharis, C. Giaginis, A. Parasi et al., “Expression of peroxisome proliferator-activated receptor-? in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival,” Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2305–2311, 2007. View at Publisher · View at Google Scholar
  130. D. Bonofiglio, S. Gabriele, S. Aquila et al., “Peroxisome proliferator-activated receptor ? activates fas ligand gene promoter inducing apoptosis in human breast cancer cells,” Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 423–434, 2009. View at Publisher · View at Google Scholar
  131. H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391–397, 2003. View at Publisher · View at Google Scholar
  132. W. L. Read, M. Q. Baggstrom, P. M. Fracasso, and R. Govindan, “A phase I study of bexarotene and rosiglitazone in patients with refractory cancers,” Chemotherapy, vol. 54, no. 3, pp. 236–241, 2008. View at Publisher · View at Google Scholar
  133. P. Hau, L. Kunz-Schughart, U. Bogdahn et al., “Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-? agonists in recurrent high-grade gliomas—a phase II study,” Oncology, vol. 73, no. 1-2, pp. 21–25, 2008. View at Publisher · View at Google Scholar
  134. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476–1481, 2007. View at Publisher · View at Google Scholar
  135. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, “Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials,” Diabetes Care, vol. 31, no. 7, pp. 1455–1460, 2008. View at Publisher · View at Google Scholar
  136. Z. Huang, S. E. Hankinson, G. A. Colditz et al., “Dual effects of weight and weight gain on breast cancer risk,” Journal of the American Medical Association, vol. 278, no. 17, pp. 1407–1411, 1997. View at Google Scholar
  137. L. M. Morimoto, E. White, Z. Chen et al., “Obesity, body size, and risk of postmenopausal breast cancer: the women's health initiative (United States),” Cancer Causes and Control, vol. 13, no. 8, pp. 741–751, 2002. View at Publisher · View at Google Scholar
  138. R. J. Cleveland, S. M. Eng, P. E. Abrahamson et al., “Weight gain prior to diagnosis and survival from breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 9, pp. 1803–1811, 2007. View at Publisher · View at Google Scholar
  139. J. Ahn, A. Schatzkin, J. V. Lacey Jr. et al., “Adiposity, adult weight change, and postmenopausal breast cancer risk,” Archives of Internal Medicine, vol. 167, no. 19, pp. 2091–2102, 2007. View at Publisher · View at Google Scholar
  140. A. H. Eliassen, G. A. Colditz, B. Rosner, W. C. Willett, and S. E. Hankinson, “Adult weight change and risk of postmenopausal breast cancer,” Journal of the American Medical Association, vol. 296, no. 2, pp. 193–201, 2006. View at Publisher · View at Google Scholar
  141. H. Poirier, J. S. Shapiro, R. J. Kim, and M. A. Lazar, “Nutritional supplementation with trans-10, cis-12-conjugated linoleic acid induces inflammation of white adipose tissue,” Diabetes, vol. 55, no. 6, pp. 1634–1641, 2006. View at Publisher · View at Google Scholar
  142. P. C. LaRosa, J. Miner, Y. Xia, Y. Zhou, S. Kachman, and M. E. Fromm, “Trans-10, cis-12 conjugated linoleic acid causes inflammation and delipidation of white adipose tissue in mice: a microarray and histological analysis,” Physiological Genomics, vol. 27, no. 3, pp. 282–294, 2006. View at Publisher · View at Google Scholar
  143. W. G. Jiang, A. Redfern, R. P. Bryce, and R. E. Mansel, “Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of γ linolenic acid in breast cancer cells,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 62, no. 2, pp. 119–127, 2000. View at Publisher · View at Google Scholar
  144. D. Shao, S. M. Rangwala, S. T. Bailey, S. L. Krakow, M. J. Reginato, and M. A. Lazar, “Interdomain communication regulating ligand binding by PPAR-γ,” Nature, vol. 396, no. 6709, pp. 377–380, 1998. View at Publisher · View at Google Scholar
  145. H. Li, X. Z. Ruan, S. H. Powis et al., “EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-?-dependent mechanism,” Kidney International, vol. 67, no. 3, pp. 867–874, 2005. View at Publisher · View at Google Scholar
  146. M. Armoni, C. Harel, F. Bar-Yoseph, S. Milo, and E. Karnieli, “Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements,” Journal of Biological Chemistry, vol. 280, no. 41, pp. 34786–34795, 2005. View at Publisher · View at Google Scholar
  147. S. Sierra, F. Lara-Villoslada, M. Comalada, M. Olivares, and J. Xaus, “Dietary fish oil n-3 fatty acids increase regulatory cytokine production and exert anti-inflammatory effects in two murine models of inflammation,” Lipids, vol. 41, no. 12, pp. 1115–1125, 2006. View at Publisher · View at Google Scholar
  148. P. C. Calder, “n-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic,” Lipids, vol. 38, no. 4, pp. 343–352, 2003. View at Publisher · View at Google Scholar
  149. M. D. Brown, C. A. Hart, E. Gazi, S. Bagley, and N. W. Clarke, “Promotion of prostatic metastatic migration towards human bone marrow stoma by omega 6 and its inhibition by omega 3 PUFAs,” British Journal of Cancer, vol. 94, no. 6, pp. 842–853, 2006. View at Publisher · View at Google Scholar
  150. F. Zapata-Gonzalez, F. Rueda, J. Petriz et al., “Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR?: RXR heterodimers: comparison with other polyunsaturated fatty acids,” Journal of Leukocyte Biology, vol. 84, no. 4, pp. 1172–1182, 2008. View at Publisher · View at Google Scholar
  151. H. Sun, I. M. Berquin, R. T. Owens, J. T. O'Flaherty, and I. J. Edwards, “Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells,” Cancer Research, vol. 68, no. 8, pp. 2912–2919, 2008. View at Publisher · View at Google Scholar
  152. T. M. Covey, K. Edes, and F. A. Fitzpatrick, “Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor,” Oncogene, vol. 26, no. 39, pp. 5784–5792, 2007. View at Publisher · View at Google Scholar
  153. M. Hughes-Fulford, C.-F. Li, J. Boonyaratanakornkit, and S. Sayyah, “Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer,” Cancer Research, vol. 66, no. 3, pp. 1427–1433, 2006. View at Publisher · View at Google Scholar
  154. U. P. Kelavkar, J. Hutzley, R. Dhir, P. Kim, K. G. D. Allen, and K. McHugh, “Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy,” Neoplasia, vol. 8, no. 2, pp. 112–124, 2006. View at Publisher · View at Google Scholar
  155. A. P. Simopoulos, “The importance of the ratio of omega-6/omega-3 essential fatty acids,” Biomedicine and Pharmacotherapy, vol. 56, no. 8, pp. 365–379, 2002. View at Publisher · View at Google Scholar
  156. W. G. Jiang, A. Redfern, R. P. Bryce, and R. E. Mansel, “Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of γ linolenic acid in breast cancer cells,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 62, no. 2, pp. 119–127, 2000. View at Publisher · View at Google Scholar
  157. S. R. Thoennes, P. L. Tate, T. M. Price, and M. W. Kilgore, “Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells,” Molecular and Cellular Endocrinology, vol. 160, no. 1-2, pp. 67–73, 2000. View at Publisher · View at Google Scholar
  158. A. Kawashima, T. Harada, K. Imada, T. Yano, and K. Mizuguchi, “Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1β-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-γ,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 79, no. 1-2, pp. 59–65, 2008. View at Publisher · View at Google Scholar
  159. C. D. Allred, D. R. Talbert, R. C. Southard, X. Wang, and M. W. Kilgore, “PPARγ1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells,” Journal of Nutrition, vol. 138, no. 2, pp. 250–256, 2008. View at Google Scholar
  160. R. Hammamieh, N. Chakraborty, S.-A. Miller et al., “Differential effects of omega-3 and omega-6 fatty acids on gene expression in breast cancer cells,” Breast Cancer Research and Treatment, vol. 101, no. 1, pp. 7–16, 2007. View at Publisher · View at Google Scholar
  161. D. P. Rose, M. A. Hatala, J. M. Connolly, and J. Rayburn, “Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in nude mice,” Cancer Research, vol. 53, no. 18, pp. 4686–4690, 1993. View at Google Scholar
  162. L. D. Yee, D. C. Young, T. J. Rosol, A. M. VanBuskirk, and S. K. Clinton, “Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARγ ligand rosiglitazone,” Journal of Nutrition, vol. 135, no. 5, pp. 983–988, 2005. View at Google Scholar
  163. E. Horia and B. A. Watkin, “Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells,” Carcinogenesis, vol. 28, no. 4, pp. 809–815, 2007. View at Google Scholar
  164. A. Angelucci, S. Garofalo, S. Speca et al., “Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells,” Endocrine-Related Cancer, vol. 15, no. 1, pp. 91–100, 2008. View at Publisher · View at Google Scholar
  165. P. Iyengar, V. Espina, T. W. Williams et al., “Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1163–1176, 2005. View at Publisher · View at Google Scholar
  166. J. E. Celis, J. M. A. Moreira, T. Cabezon et al., “Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions,” Molecular and Cellular Proteomics, vol. 4, no. 4, pp. 492–522, 2005. View at Publisher · View at Google Scholar
  167. L. H. Wang, X. Y. Yang, X. Zhang, and W. L. Farrar, “Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBPβ,” Blood, vol. 110, no. 13, pp. 4373–4384, 2007. View at Publisher · View at Google Scholar
  168. J. Kim, P. Yang, M. Suraokar et al., “Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products,” Cancer Research, vol. 65, no. 14, pp. 6189–6198, 2005. View at Publisher · View at Google Scholar
  169. G. P. Vandoros, P. A. Konstantinopoulos, G. Sotiropoulou-Bonikou et al., “PPAR-? is expressed and NF-?B pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 2, pp. 76–84, 2006. View at Publisher · View at Google Scholar
  170. H. J. Kim, J.-Y. Hwang, H. J. Kim et al., “Expression of a peroxisome proliferator-activated receptor ?1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress,” Clinical Cancer Research, vol. 13, no. 9, pp. 2577–2583, 2007. View at Publisher · View at Google Scholar
  171. G. Kristiansen, J. Jacob, A.-C. Buckendahl et al., “Peroxisome proliferator-activated receptor ? is highly expressed in pancreatic cancer and is associated with shorter overall survival times,” Clinical Cancer Research, vol. 12, no. 21, pp. 6444–6451, 2006. View at Publisher · View at Google Scholar
  172. S. Kulkarni, D. B. Patil, L. K. Diaz, E. L. Wiley, M. Morrow, and S. A. Khan, “COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ,” BMC Cancer, vol. 8, article 36, 2008. View at Publisher · View at Google Scholar
  173. T. Suzuki, S. Hayashi, Y. Miki et al., “Peroxisome proliferator-activated receptor ? in human breast carcinoma: a modulator of estrogenic actions,” Endocrine-Related Cancer, vol. 13, no. 1, pp. 233–250, 2006. View at Publisher · View at Google Scholar
  174. J. Padilla, K. Kaur, H. J. Cao, T. J. Smith, and R. P. Phipps, “Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells,” Journal of Immunology, vol. 165, no. 12, pp. 6941–6948, 2000. View at Google Scholar
  175. J. A. Keelan, T. A. Sato, K. W. Marvin, J. Lander, R. S. Gilmour, and M. D. Mitchell, “15-deoxy-Δ12,14-prostaglandin J2 a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells,” Biochemical and Biophysical Research Communications, vol. 262, no. 3, pp. 579–585, 1999. View at Publisher · View at Google Scholar
  176. D.-H. Nam, S. Ramachandran, D.-K. Song et al., “Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR ? ligand ciglitizone,” Molecular Human Reproduction, vol. 13, no. 11, pp. 829–836, 2007. View at Publisher · View at Google Scholar